Skip to content
Options Trading Report

Options Trading Report

Primary Menu
  • Home
  • Business
  • Domestic
  • Economy
  • Money
  • Top News
  • Newsletters
  • Home
  • 2024
  • October
  • Exclusive-CVS to exit core infusions services business, job cuts possible

Exclusive-CVS to exit core infusions services business, job cuts possible

Editor October 11, 2024 2 minutes read

By Amina Niasse

NEW YORK (Reuters) -CVS Health is exiting its core infusion services business and plans to either close or sell 29 related regional pharmacies in the coming months, a company spokesperson confirmed to Reuters on Friday.

Details of the strategic shift were announced in a CVS corporate memo dated Oct. 8 and seen by Reuters.

The company on Oct. 8 stopped taking new patients seeking antibiotics, drugs supporting muscular health, and intravenous nutrition services, Shelly Bandit, a senior manager of corporate communications, told Reuters.

CVS bought Coram LLC, a drug infusion services provider, for $2.1 billion in 2013.

“Providers of infused medications have continued to face a challenging environment for their most highly specialized, complex services, and Coram has not been immune to these challenges,” Bandit added.

It will continue to provide specialty medications and enteral nutrition, or tube feeding, at pharmacies in Minnesota, Pennsylvania and San Diego, and provide nursing services nationwide.

She said the company has not yet announced any workforce reductions and that any impacted employees would be notified in mid-November with the roles ending in January.

Patients still relying on the targeted therapies will be transferred to other infusion providers, Bandit said.

The move is not related to the company’s plan to cut 2,900 corporate jobs.

“We plan to close 29 regional pharmacies over the coming months, but are also exploring a possible sale of these assets,” Bandit said.

Reuters reported in September that CVS is exploring a split between its insurance and retail businesses, amid active investor scrutiny. Expecting higher medical costs during the second-half of 2024, the company slashed its earnings forecast in August.

Coram provides on-site infusions, as well as in-home therapies, according to Bandit. Coram’s Rhode Island location will also remain open, she said.

CVS shares were flat at $66.91 on Friday afternoon.

(Reporting by Amina NiasseEditing by Caroline Humer and Bill Berkrot)

About the Author

Editor

Administrator

Visit Website View All Posts

Post navigation

Previous: Stocks rise on lift from bank earnings, US yields dip
Next: US expands sanctions against Iran’s ‘ghost fleet’ of oil tankers

Live Market Pulse

The charting technology is provided by TradingView. Learn how to use theTradingView Stock Screener.

Want More Market News?
Add your email address below to get up to date market news and more!
By submitting your email address, you'll receive a free subscription to Options Trading Report newsletter (Privacy Policy). These newsletters are completely free - and always will be. You will also receive occasional offers about products and services available to you from our affiliates. You can unsubscribe at any time.

Search

Recent Posts

  • The Options Trader’s Playbook: Week of April 27
  • Apple’s Services Machine Is the Real Story Heading Into WWDC 2026
  • The Barbell Consumer
  • An Historic Economy – by Justin Vaughn, Editor, Options Trading Report
  • Meta strikes deal with Amazon’s cloud unit to use its CPU chipsĀ 

Categories

  • Business
  • Domestic
  • Economy
  • Market News
  • Newsletters
  • Options
  • Reflections
  • Top News

You may have missed

  • Newsletters

The Options Trader’s Playbook: Week of April 27

Editor April 26, 2026
  • Newsletters

Apple’s Services Machine Is the Real Story Heading Into WWDC 2026

Editor April 25, 2026
photo-1611974789855-9c2a0a7236a3?auto=format&fit=crop&w=1200&q=80
  • Newsletters

The Barbell Consumer

Editor April 24, 2026
ChatGPT Image Apr 24, 2026, 11_57_50 AM
  • Market News

An Historic Economy – by Justin Vaughn, Editor, Options Trading Report

Editor April 24, 2026
  • Home
  • Terms of Service
  • Privacy Policy
  • Disclaimer
  • Contact Us
Copyright 2026 © All rights reserved | Options Trading Report | optionstradingreport.com SITE_OK